Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 64

Results For "cancer"

1093 News Found

Biocon Biologics' Hulio Biosimilar to Humira now available in the US
News | July 04, 2023

Biocon Biologics' Hulio Biosimilar to Humira now available in the US

The launch of HULIO in the United States is an important milestone for Biocon Biologics


Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
News | June 30, 2023

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully


Shilpa Medicare launches Lenvatinib Capsules in India under the brand name Lenshil
News | June 30, 2023

Shilpa Medicare launches Lenvatinib Capsules in India under the brand name Lenshil

The company is already marketing the 4 mg and 10 mg strengths


Granules India and Central Bureau of Narcotics unite to tackle drug abuse
News | June 29, 2023

Granules India and Central Bureau of Narcotics unite to tackle drug abuse

Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society


Eugia Pharma signs voluntary license with Medicines Patent Pool to develop generic version of Nilotinib Capsules
News | June 24, 2023

Eugia Pharma signs voluntary license with Medicines Patent Pool to develop generic version of Nilotinib Capsules

The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India


USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
Drug Approval | June 19, 2023

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma


Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders
News | June 19, 2023

Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders

Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses


SMi discloses £6 million seed funding round, bolsters team with new C-suite hire
News | June 15, 2023

SMi discloses £6 million seed funding round, bolsters team with new C-suite hire

Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics


Baghel inaugurates the World Blood Donor Day at RML Hospital
News | June 15, 2023

Baghel inaugurates the World Blood Donor Day at RML Hospital

The slogan for this year's World Blood Donor Day campaign is 'Give blood, give plasma, share life, share often'


Astellas submits new drug application for Zolbetuximab in Japan
News | June 13, 2023

Astellas submits new drug application for Zolbetuximab in Japan

Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers